Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00062894 | Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | PHASE1 | COMPLETED | 12 | — | — | Apr 1, 2003 | Apr 1, 2007 | Sep 17, 2007 | 6 | United States |
| Name | Type | Description |
|---|---|---|
| Iodine I 131 Tositumomab | DRUG | - |
Inclusion Criteria: * At least 18 years of age * Histologically confirmed diagnosis of follicular lymphoma, Grade 1, 2, or 3, or diffuse large cell lymphoma (WHO/REAL classification). Follicular, small cleaved; Follicular, mixed small cleaved and large cell; Follicular large cell lymphoma Transfor...